Clinical and Operational Implementation of Ansuvimab under Expanded Access for Ebola Patients in the Democratic Republic of the Congo.

Authors

Sabue Mulangu, Jepsy Yango, Felicia Lipansky, Gael Mukendi, Donatien Kazadi, Celestin Tshimanga, Grace Lobo, Merveilles Kankonde, Mariano Lusakibanza, Nsengi Ntamabyaliro, Placide Mbala, Wendy P Painter, Jean Jacques Muyembe

Published in

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. Pages 109148. Sep 27, 2026. Epub Sep 27, 2026.

Abstract

Ebola Virus Disease (EVD) is a zoonosis caused by Orthoebolavirus zairense (EBOV). Outbreaks of EVD have occurred in the Democratic Republic of Congo (DRC), and an Expanded Access Program (EAP) with ansuvimab was implemented.
The primary objectives were to treat individuals with EBOV infection and to provide post-exposure prophylaxis (PEP) to those with high-risk exposure.
We reported a descriptive expanded-access case series from the 11th, 12th, and 13^th EVD outbreaks in the DRC. Following each outbreak declaration, the ansuvimab EAP protocol was updated and approved by the ethics committee. Eligible participants received ansuvimab intravenously.
Twenty-four participants with confirmed EBOV infection and three PEP participants received ansuvimab during the 11th, 12th, and 13th EVD outbreaks. Most treated participants received ansuvimab within 7 days of symptom onset. Three of 24 EBOV-infected participants died; all three had baseline high viral load. No PEP participant developed EVD. No serious adverse events or new safety signals were identified CONCLUSIONS: Rapid protocol adaptation, ethics review, and in-country product storage enabled ansuvimab delivery during EVD outbreaks. Favorable clinical outcomes were consistent with previous findings, although small sample size, lack of a comparator, and predominance of participants with lower viral load limited interpretation.

PMID:
42801990
Bibliographic data and abstract were imported from PubMed on 28 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.